Okay, let's tackle this question. The patient is a 29-year-old woman with joint pain and swelling in both hands, specifically affecting the proximal interphalangeal (PIP) and metacarpophalangeal (MCP) joints. She has morning stiffness, a positive rheumatoid factor (RF), and a negative antinuclear antibody (ANA). The question is asking which medication would most likely improve her joint pain.

First, I need to figure out the diagnosis. The symptoms described are classic for rheumatoid arthritis (RA). RA typically presents with symmetric joint involvement, especially in the small joints of the hands and feet. Morning stiffness lasting more than 30 minutes is a hallmark. The presence of RF supports this, although it's important to note that not all RA patients are RF positive. The negative ANA makes systemic lupus erythematosus (SLE) less likely, as ANA is usually positive in SLE.

Now, the treatment options for RA. The mainstay of treatment for RA is disease-modifying antirheumatic drugs (DMARDs). The first-line DMARD is methotrexate. It works by inhibiting dihydrofolate reductase, which is involved in purine synthesis. This reduces the proliferation of immune cells and inflammation. Other DMARDs include leflunomide, sulfasalazine, and hydroxychloroquine. Biologics like TNF-alpha inhibitors (e.g., etanercept, infliximab) are used if DMARDs are not effective or well-tolerated.

The question is about which medication would improve joint pain. So, the correct answer should be a DMARD, likely methotrexate. Let's consider the options. If the options include methotrexate, that's the answer. Other options might be NSAIDs, corticosteroids, or other DMARDs. NSAIDs can help with pain and inflammation but don't modify the disease course. Corticosteroids are used for short-term relief or in severe cases. So, the correct answer is the DMARD, specifically methotrexate.

Now, looking at the wrong options. If the options included NSAIDs like ibuprofen, that's incorrect because they don't address the underlying disease process. Corticosteroids might reduce inflammation but aren't the first-line treatment for RA. Another DMARD like sulfasalazine could be a distractor but methotrexate is the first-line. Also, if there was a biologic agent, that's used after DMARDs. So, the correct answer is methotrexate.

**Core Concept**
This scenario describes a classic presentation of **rheumatoid arthritis (RA)**, characterized by symmetric joint involvement, morning stiffness, and a positive rheumatoid factor (RF). The primary treatment goal is to use **disease-modifying antirheumatic drugs (DMARDs)** to reduce inflammation and prevent joint damage.

**Why the Correct Answer is Right**
**Methotrexate**, a first-line DMARD, is the most effective therapy for RA. It inhibits **dihydrofolate reductase**, impairing purine synthesis and reducing immune cell proliferation. This action suppresses synovial inflammation, alleviates joint pain, and slows disease progression. Its efficacy in early RA makes it the standard

✓ Correct Answer: D. NSAID or aspirin